- Home
- AKBA vs IRAB Comparison
AKBA vs IRAB Comparison
Compare AKBA & IRAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AKBA | IRAB |
|---|---|---|
| Founded | 2007 | 2025 |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 229.3M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AKBA | IRAB |
|---|---|---|
| Price | $0.57 | $10.03 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 9.5M | 81.2K |
| Earning Date | 11-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $9.82 |
| 52 Week High | $1.84 | $10.17 |
Technical Indicators
Market Signals| Indicator | AKBA | IRAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 52.34 |
| Support Level | $0.54 | $9.99 |
| Resistance Level | $1.00 | $10.05 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 45.81 | 22.22 |
Price Performance
Historical ComparisonAbout AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
About IRAB Iris Acquisition Corp II Class A Ordinary Shares
Iris Acquisition Corp II is a blank check company.